Lv61
2255 积分 2022-04-04 加入
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
1个月前
已完结
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
3个月前
已完结
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
4个月前
已完结
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
4个月前
已完结
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)
5个月前
已完结
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)
5个月前
已完结
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
5个月前
已完结
Cefiderocol Pharmacokinetics in Critically-ill Patients Receiving Extra-Corporeal Membrane Oxygenation (ECMO)
6个月前
已完结
皖公网安备34019202002308
